21 results on '"Zi-Ying Wang"'
Search Results
2. β-arrestin2 deficiency ameliorates S-100-induced autoimmune hepatitis in mice by inhibiting infiltration of monocyte-derived macrophage and attenuating hepatocyte apoptosis
- Author
-
Ting-ting Chen, Xiu-qin Li, Nan Li, Ya-ping Xu, Yu-han Wang, Zi-ying Wang, Sheng-nan Zhang, Meng Qi, Shi-hao Zhang, Wei Wei, Hua Wang, and Wu-yi Sun
- Subjects
Pharmacology ,Pharmacology (medical) ,General Medicine - Published
- 2023
3. CP-25 exerts a protective effect against ConA-induced hepatitis via regulating inflammation and immune response
- Author
-
Nan Li, Jing-Jing Wu, Meng Qi, Zi-Ying Wang, Sheng-Nan Zhang, Xiu-Qin Li, Ting-Ting Chen, Mei-Fang Wang, Ling-Ling Zhang, Wei Wei, and Wu-Yi Sun
- Subjects
Pharmacology ,Pharmacology (medical) - Abstract
Hepatitis is a complex multifactorial pathological disorder, which can eventually lead to liver failure and even potentially be life threatening. Paeoniflorin-6′-O-benzene sulfonate (CP-25) has proven to have critical anti-inflammatory effects in arthritis. However, the effects of CP-25 in the pathogenesis of hepatitis remains unclear. In this experiment, mice were intragastrically administered with CP-25 (25, 50 and 100 mg/kg), and then ConA (25 mg/kg) was intravenous injected to establish hepatitis model in vivo. CP-25 administration attenuated liver damage and decreased ALT and AST activities in mice with hepatitis. Besides, CP-25 modulated immune responses including down-regulated the proportions of activated CD4+, activated CD8+ T cells, and ratio of Th1/Th2 in ConA-injected mice. Furthermore, ConA-mediated production of reactive oxygen species (ROS), release of inflammatory cytokines including IFN-γ, TNF-α, activation of MAPK pathways and nuclear translocation of nuclear factor-kappaB (NF-κB) were significantly decreased in CP-25 administrated mice. In ConA-stimulated RAW264.7 cells, CP-25 suppressed inflammatory cytokines secretion and reduced ROS level, which were consistent with animal experiments. Otherwise, the data showed that CP-25 restrained phosphorylation of ERK, JNK and p38 MAPK pathways influenced by ROS, accompanied with inhibiting NF-κB nuclear translocation. In conclusion, our findings indicated that CP-25 protected against ConA-induced hepatitis may through modulating immune responses and attenuating ROS-mediated inflammation via the MAPK/NF-κB signaling pathway.
- Published
- 2022
4. TFEB, a master regulator of autophagy and biogenesis, unexpectedly promotes apoptosis in response to the cyclopentenone prostaglandin 15d-PGJ2
- Author
-
Zhou Zhu, Chuanbin Yang, Zi-Ying Wang, Jieqiong Tan, Benjamin Chun-Kit Tong, Ashok Iyaswamy, Min Li, Jia-Hong Lu, Cheng-Fu Su, Ju-Xian Song, Senthilkumar Krishnamoorthi, Jia Liu, Shi-Ying Huang, King-Ho Cheung, Sravan Gopalkrishnashetty Sreenivasmurthy, and Jia-Xi Wu
- Subjects
Pharmacology ,Prostaglandin D2 ,Autophagy ,ATF4 ,Apoptosis ,Cyclopentanes ,General Medicine ,mTORC1 ,Cycloheximide ,Article ,Cell biology ,chemistry.chemical_compound ,medicine.anatomical_structure ,chemistry ,Downregulation and upregulation ,Lysosome ,Prostaglandins ,Unfolded protein response ,medicine ,TFEB ,Pharmacology (medical) ,Reactive Oxygen Species - Abstract
Transcriptional factor EB (TFEB), a master regulator of autophagy and lysosomal biogenesis, is generally regarded as a pro-survival factor. Here, we identify that besides its effect on autophagy induction, TFEB exerts a pro-apoptotic effect in response to the cyclopentenone prostaglandin 15-deoxy-∆-(12,14)-prostaglandin J2 (15d-PGJ2). Specifically, 15d-PGJ2 promotes TFEB translocation from the cytoplasm into the nucleus to induce autophagy and lysosome biogenesis via reactive oxygen species (ROS) production rather than mTORC1 inactivation. Surprisingly, TFEB promotes rather than inhibits apoptosis in response to 15d-PGJ2. Mechanistically, ROS-mediated TFEB translocation into the nucleus transcriptionally upregulates the expression of ATF4, which is required for apoptosis elicited by 15d-PGJ2. Additionally, inhibition of TFEB activation by ROS scavenger N-acetyl cysteine or inhibition of protein synthesis by cycloheximide effectively compromises ATF4 upregulation and apoptosis in response to 15d-PGJ2. Collectively, these results indicate that ROS-induced TFEB activation exerts a novel role in promoting apoptosis besides its role in regulating autophagy in response to 15d-PGJ2. This work not only evidences how TFEB is activated by 15d-PGJ2, but also unveils a previously unexplored role of ROS-dependent activation of TFEB in modulating cell apoptosis in response to 15d-PGJ2.
- Published
- 2021
5. Transcription factor EB: an emerging drug target for neurodegenerative disorders
- Author
-
Min Li, Zi-Ying Wang, Jia Liu, Jiang Yimin, and Ju-Xian Song
- Subjects
0301 basic medicine ,Pharmacology ,Basic Helix-Loop-Helix Leucine Zipper Transcription Factors ,business.industry ,Drug target ,Autophagy-Related Proteins ,Brain ,Proteins ,Master regulator ,Neurodegenerative Diseases ,Small molecule ,03 medical and health sciences ,030104 developmental biology ,0302 clinical medicine ,Drug development ,030220 oncology & carcinogenesis ,Drug Discovery ,Cancer research ,Humans ,Medicine ,TFEB ,Molecular Targeted Therapy ,business ,Signal Transduction - Abstract
The discovery of transcription factor EB (TFEB) as a master regulator of the autophagy-lysosomal pathway (ALP) has triggered increasing numbers of studies that aim to explore the therapeutic potential of targeting TFEB to treat neurodegenerative disorders (NDs) such as Alzheimer's disease and Parkinson's disease. So far, the findings are exciting and promising. Here, we delineate the dysfunction of the TFEB-mediated ALP in NDs, and we summarize small molecules that have been identified as TFEB activators, along with their protective effects in NDs. We discuss the molecular mechanisms and targets, and the pros and cons of these TFEB activators from the perspective of drug development. Specific and potent small-molecule TFEB activators with ideal brain bioavailability could provide a method for treating NDs.
- Published
- 2021
6. Lemairamin, isolated from the Zanthoxylum plants, alleviates pain hypersensitivity via spinal α7 nicotinic acetylcholine receptors
- Author
-
Meng-Jing Zhao, Yong-Xiang Wang, Rana Muhammad Shoaib, Zi-Ying Wang, Evhy Apryani, Meng-Yan Deng, Qiao-Qiao Han, and Dong-Qing Wei
- Subjects
Male ,Zanthoxylum ,0301 basic medicine ,Agonist ,alpha7 Nicotinic Acetylcholine Receptor ,medicine.drug_class ,Aconitine ,Biophysics ,Minocycline ,Pharmacology ,Biochemistry ,Mice ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Formaldehyde ,Animals ,Medicine ,Rats, Wistar ,Molecular Biology ,Injections, Spinal ,Neuroinflammation ,Methyllycaconitine ,Acrylamides ,Analgesics ,Naloxone ,business.industry ,beta-Endorphin ,Antagonist ,Cancer Pain ,Cell Biology ,Interleukin-10 ,Rats ,Interleukin 10 ,030104 developmental biology ,Nociception ,Spinal Cord ,chemistry ,Hyperalgesia ,030220 oncology & carcinogenesis ,Neuropathic pain ,Neuralgia ,Female ,Microglia ,business ,medicine.drug - Abstract
Lemairamin (also known as wgx-50), is isolated from the pericarps of the Zanthoxylum plants. As an agonist of α7 nicotinic acetylcholine receptors (α7nAChRs), it can reduce neuroinflammation in Alzheimer's disease. This study evaluated its antinociceptive effects in pain hypersensitivity and explored the underlying mechanisms. The data showed that subcutaneous lemairamin injection dose-dependently inhibited formalin-induced tonic pain but not acute nociception in mice and rats, while intrathecal lemairamin injection also dose-dependently produced mechanical antiallodynia in the ipsilateral hindpaws of neuropathic and bone cancer pain rats without affecting mechanical thresholds in the contralateral hindpaws. Multiple bi-daily lemairamin injections for 7 days did not induce mechanical antiallodynic tolerance in neuropathic rats. Moreover, the antinociceptive effects of lemairamin in formalin-induced tonic pain and mechanical antiallodynia in neuropathic pain were suppressed by the α7nAChR antagonist methyllycaconitine. In an α7nAChR antagonist-reversible manner, intrathecal lemairamin also stimulated spinal expression of IL-10 and β-endorphin, while lemairamin treatment induced IL-10 and β-endorphin expression in primary spinal microglial cells. In addition, intrathecal injection of a microglial activation inhibitor minocycline, anti-IL-10 antibody, anti-β-endorphin antiserum or μ-opioid receptor-preferred antagonist naloxone was all able to block lemairamin-induced mechanical antiallodynia in neuropathic pain. These data demonstrated that lemairamin could produce antinociception in pain hypersensitivity through the spinal IL-10/β-endorphin pathway following α7nAChR activation.
- Published
- 2020
7. NeuroDefend, a novel Chinese medicine, attenuates amyloid-β and tau pathology in experimental Alzheimer's disease models
- Author
-
Huan Zhang, Chuanbin Yang, Zhou Zhu, Min Li, Zi-Ying Wang, Jia-Hong Lu, Sandeep Malampati, Benjamin Chun-Kit Tong, Ju-Xian Song, Ashok Iyaswamy, King-Ho Cheung, Siva Sundara Kumar Durairajan, Senthilkumar Krishnamoorthi, Venkatapathy Kaliyamoorthy, and Sravan Gopalkrishnashetty Sreenivasmurthy
- Subjects
Amyloid β ,030309 nutrition & dietetics ,Transgene ,Mice, Transgenic ,tau Proteins ,lcsh:TX341-641 ,Traditional Chinese medicine ,Disease ,Pharmacology ,Protein aggregation ,Protein Aggregation, Pathological ,01 natural sciences ,Mice ,03 medical and health sciences ,Alzheimer Disease ,Oral administration ,mental disorders ,medicine ,Animals ,Medicine, Chinese Traditional ,0303 health sciences ,Amyloid beta-Peptides ,business.industry ,010401 analytical chemistry ,lcsh:RM1-950 ,Brain ,Symptomatic relief ,0104 chemical sciences ,Disease Models, Animal ,medicine.anatomical_structure ,lcsh:Therapeutics. Pharmacology ,Neuron ,business ,lcsh:Nutrition. Foods and food supply ,Drugs, Chinese Herbal ,Food Science - Abstract
Alzheimer's disease (AD) is the most common age-related neurodegenerative disorder. Amyloid-β (Aβ) and hyper-phosphorylated tau accumulation are accountable for the progressive neuronal loss and cognitive impairments usually observed in AD. Currently, medications for AD offer moderate symptomatic relief but fail to cure the disease; hence development of effective and safe drugs is urgently needed for AD treatment. In this study, we investigated a Chinese medicine (CM) formulation named NeuroDefend (ND), for reducing amyloid β (Aβ) and tau pathology in transgenic AD mice models. Regular oral administration of ND improved cognitive function and memory in 3XTg-AD and 5XFAD mice. In addition, ND reduced beta-amyloid precursor protein (APP), APP C-terminal fragments (CTF-β/α), Aβ and 4G8 positive Aβ burden in 3XTg-AD and 5XFAD mice. Furthermore, ND efficiently reduced the levels of insoluble phospho-tau protein aggregates and AT8 positive phospho tau neuron load in 3XTg-AD mice. Hence, ND could be a promising candidate for the treatment of AD in humans. Keywords: Alzheimer's disease, Aβ-plaque, Neurofibrillary tangles, Chinese medicine, NeuroDefend
- Published
- 2020
8. Qingyangshen mitigates amyloid-β and Tau aggregate defects involving PPARα-TFEB activation in transgenic mice of Alzheimer's disease
- Author
-
Zi-Ying Wang, Ashok Iyaswamy, Xin-Jie Guan, Min Li, Zhou Zhu, Sravan Gopalkrishnashetty Sreenivasmurthy, Senthilkumar Krishnamoorthi, Huan Zhang, Cheng-Fu Su, King-Ho Cheung, Siva Sundara Kumar Durairajan, Ju-Xian Song, and Jia Liu
- Subjects
Genetically modified mouse ,Pharmaceutical Science ,Mice, Transgenic ,tau Proteins ,Pharmacology ,Microgliosis ,Neuroprotection ,Amyloid beta-Protein Precursor ,Mice ,In vivo ,Alzheimer Disease ,Drug Discovery ,Amyloid precursor protein ,Animals ,PPAR alpha ,Amyloid beta-Peptides ,biology ,Chemistry ,Basic Helix-Loop-Helix Leucine Zipper Transcription Factors ,In vitro ,Disease Models, Animal ,Complementary and alternative medicine ,biology.protein ,Molecular Medicine ,TFEB ,Astrocytosis ,Drugs, Chinese Herbal - Abstract
Background Alzheimer's disease (AD) is the most common neurodegenerative disease. Deposition of amyloid β plaques (Aβ) and neurofibrillary tangles (NFTs) is the key pathological hallmark of AD. Accumulating evidence suggest that impairment of autophagy-lysosomal pathway (ALP) plays key roles in AD pathology. Purpose The present study aims to assess the neuroprotective effects of Qingyangshen (QYS), a Chinese herbal medicine, in AD cellular and animal models and to determine its underlying mechanisms involving ALP regulation. Methods QYS extract was prepared and its chemical components were characterized by LC/MS. Then the pharmacokinetics and acute toxicity of QYS extract were evaluated. The neuroprotective effects of QYS extract were determined in 3XTg AD mice, by using a series of behavioral tests and biochemical assays, and the mechanisms were examined in vitro. Results Oral administration of QYS extract improved learning and spatial memory, reduced carboxy-terminal fragments (CTFs), amyloid precursor protein (APP), Aβ and Tau aggregates, and inhibited microgliosis and astrocytosis in the brains of 3XTg mice. Mechanistically, QYS extract increased the expression of PPARα and TFEB, and promoted ALP both in vivo and in vitro. Conclusion QYS attenuates AD pathology, and improves cognitive function in 3XTg mice, which may be mediated by activation of PPARα-TFEB pathway and the subsequent ALP enhancement. Therefore, QYS may be a promising herbal material for further anti-AD drug discovery.
- Published
- 2021
9. Cynandione A Alleviates Neuropathic Pain Through α7-nAChR-Dependent IL-10/β-Endorphin Signaling Complexes
- Author
-
Min Yin, Hao Liu, Qiao-Qiao Han, Jun-Ping Ao, Zi-Ying Wang, and Yong-Xiang Wang
- Subjects
α7 nicotinic acetylcholine receptor ,p38 mitogen-activated protein kinases ,interleukin-10 ,β-endorphin ,microglia ,Dynorphin ,Pharmacology ,CREB ,chemistry.chemical_compound ,medicine ,Pharmacology (medical) ,Original Research ,neuropathic pain ,Methyllycaconitine ,cynandione A ,biology ,Microglia ,lcsh:RM1-950 ,lcsh:Therapeutics. Pharmacology ,medicine.anatomical_structure ,chemistry ,Neuropathic pain ,biology.protein ,Phosphorylation ,Signal transduction - Abstract
Cynandione A, an acetophenone isolated from Cynanchum Wilfordii Radix, exhibits antineuropathic pain effect. This study further explored the target molecule and signaling mechanisms underlying cynandione-A-induced antineuropathic pain. Intrathecal injection of cynandione A significantly attenuated mechanical allodynia in neuropathic rats and substantially increased spinal expression of IL-10 and β-endorphin but not dynorphin A. Cynandione A treatment also enhanced expression of IL-10 and β-endorphin but not α7 nicotinic acetylcholine receptors (nAChRs) in cultured microglia. The IL-10 antibody attenuated cynandione-A-induced spinal or microglial gene expression of β-endorphin and mechanical allodynia, whereas the β-endorphin antiserum blocked cynandione-A-induced mechanical antiallodynia but not spinal or microglial IL-10 gene expression. The α7 nAChR antagonist methyllycaconitine significantly reduced cynandione-A-induced mechanical antiallodynia and spinal or microglial expression of IL-10 and β-endorphin. Furthermore, cynandione A stimulated microglial phosphorylation of PKA, p38, and CREB in an α7-nAChR-dependent manner, and treatment with their inhibitors attenuated cynandione-A-induced mechanical antiallodynia and spinal or microglial expression of IL-10 and β-endorphin. In addition, cynandione A stimulated spinal phosphorylation of the transcription factor STAT3, which was inhibited by methyllycaconitine, the PKA activation inhibitor or IL-10 antibody. The STAT3 inhibitor NSC74859 also abolished cynandione-A-induced mechanical antiallodynia and spinal expression of β-endorphin. These findings suggest that cynandione A suppresses neuropathic pain through α7-nAChR-dependent IL-10/β-endorphin signaling pathway in spinal microglia.
- Published
- 2021
10. Mouse strain specificity of DAAO inhibitors-mediated antinociception
- Author
-
Yong-Xiang Wang, Jin-miao Lu, Zi-Ying Wang, Hao Liu, Yu-Cong Zhou, Qiao-Qiao Han, Evhy Apryani, Nian Gong, and Mei-Xian Ou
- Subjects
D-Amino-Acid Oxidase ,Male ,Nociception ,D-amino acid oxidase ,hydrogen peroxide ,RM1-950 ,D‐amino acid oxidase ,Pharmacology ,030226 pharmacology & pharmacy ,03 medical and health sciences ,chemistry.chemical_compound ,Mice ,0302 clinical medicine ,medicine ,Animals ,General Pharmacology, Toxicology and Pharmaceutics ,Hydrogen peroxide ,antinociception ,chemistry.chemical_classification ,Oxidase test ,Analgesics ,Glutathione Peroxidase ,Mice, Inbred BALB C ,Glutathione peroxidase ,Oxidative deamination ,Glutathione ,Original Articles ,Mice, Inbred C57BL ,Neurology ,chemistry ,Biological Variation, Population ,Spinal Cord ,030220 oncology & carcinogenesis ,Morphine ,Original Article ,Therapeutics. Pharmacology ,medicine.drug - Abstract
D‐Amino acid oxidase (DAAO) specifically catalyzes the oxidative deamination of neutral and polar D‐amino acids and finally yields byproducts of hydrogen peroxide. Our previous work demonstrated that the spinal astroglial DAAO/hydrogen peroxide (H2O2) pathway was involved in the process of pain and morphine antinociceptive tolerance. This study aimed to report mouse strain specificity of DAAO inhibitors on antinociception and explore its possible mechanism. DAAO inhibitors benzoic acid, CBIO, and SUN significantly inhibited formalin‐induced tonic pain in Balb/c and Swiss mice, but had no antinociceptive effect in C57 mice. In contrast, morphine and gabapentin inhibited formalin‐induced tonic pain by the same degrees among Swiss, Balb/c and C57 mice. Therefore, mouse strain difference in antinociceptive effects was DAAO inhibitors specific. In addition, intrathecal injection of D‐serine greatly increased spinal H2O2 levels by 80.0% and 56.9% in Swiss and Balb/c mice respectively, but reduced spinal H2O2 levels by 29.0% in C57 mice. However, there was no remarkable difference in spinal DAAO activities among Swiss, Balb/c and C57 mice. The spinal expression of glutathione (GSH) and glutathione peroxidase (GPx) activity in C57 mice were significantly higher than Swiss and Balb/c mice. Furthermore, the specific GPx inhibitor D‐penicillamine distinctly restored SUN antinociception in C57 mice. Our results reported that DAAO inhibitors produced antinociception in a strain‐dependent manner in mice and the strain specificity might be associated with the difference in spinal GSH and GPx activity., Effects of DAAO inhibitors (CBIO, benzoic acid and SUN) were compared between Swiss, Balb/c and C57 mice in formalin test. The results showed that the DAAO inhibitors significantly inhibited formalin‐induced tonic pain in Balb/c and Swiss mice, but had no effect in C57 mice.
- Published
- 2021
11. Traditional Chinese medicine compounds regulate autophagy for treating neurodegenerative disease: A mechanism review
- Author
-
Zhou Zhu, Jia-Hong Lu, Min Li, Jia Liu, Zi-Ying Wang, Gang Chen, Ashok Iyaswamy, Ju-Xian Song, Cheng-Fu Su, and Sravan Gopalkrishnashetty Sreenivasmurthy
- Subjects
0301 basic medicine ,Autophagy-Related Proteins ,Traditional Chinese medicine ,Disease ,RM1-950 ,Neurodegenerative disease ,Neuroprotection ,03 medical and health sciences ,0302 clinical medicine ,Autophagy ,Medicine ,Animals ,Humans ,Medicine, Chinese Traditional ,Beneficial effects ,Pharmacology ,Neurons ,Mechanism (biology) ,business.industry ,Neurodegeneration ,Neurodegenerative Diseases ,General Medicine ,medicine.disease ,030104 developmental biology ,030220 oncology & carcinogenesis ,Nerve Degeneration ,Therapeutics. Pharmacology ,business ,Neuroscience ,Drugs, Chinese Herbal - Abstract
Neurodegenerative diseases (NDs) are common chronic diseases related to progressive damage of the nervous system. Globally, the number of people with an ND is dramatically increasing consistent with the fast aging of society and one of the common features of NDs is the abnormal aggregation of diverse proteins. Autophagy is the main process by which misfolded proteins and damaged organelles are removed from cells. It has been found that the impairment of autophagy is associated with many NDs, suggesting that autophagy has a vital role in the neurodegeneration process. Recently, more and more studies have reported that autophagy inducers display a protective role in different ND experimental models, suggesting that enhancement of autophagy could be a potential therapy for NDs. In this review, the evidence for beneficial effects of traditional Chinese medicine (TCM) regulate autophagy in the models of Alzheimer's disease (AD), Parkinson's disease (PD), and other NDs are presented and common autophagy-related mechanisms are identified. The results demonstrate that TCM which regulate autophagy are potential therapeutic candidates for ND treatment.
- Published
- 2021
12. Feruloylated Oligosaccharides Alleviate Central Nervous Inflammation in Mice Following Spinal Cord Contusion
- Author
-
Zi-Ying Wang, Lu Huang, Junqing Huang, Jing Li, Ling-Tai Yu, Gabriel Tao, and Wen-Zhi Hao
- Subjects
MAPK/ERK pathway ,Coumaric Acids ,Oligosaccharides ,Inflammation ,Pharmacology ,Motor Activity ,Neuroprotection ,Proinflammatory cytokine ,Mice ,Medicine ,Animals ,Humans ,Colitis ,Spinal cord injury ,Spinal Cord Injuries ,Microglia ,business.industry ,General Chemistry ,Recovery of Function ,medicine.disease ,Spinal cord ,medicine.anatomical_structure ,Spinal Cord ,Cytokines ,Female ,medicine.symptom ,General Agricultural and Biological Sciences ,business - Abstract
As one of the empirical models of the chronic central inflammatory response, a spinal cord injury (SCI) deteriorates the neuronal survival and results in irreversible motor and sensory dysfunction below the injury area. Our previous studies have reported that maize bran feruloylated oligosaccharides (FOs) exert significant anti-inflammatory activities both in diabetes and colitis. However, no direct evidence of FOs alleviating central nervous inflammation was stated. This study aimed to investigate the therapeutic effect of FOs on SCI and its potential mechanism. Our results indicated that 4 weeks of FO administration effectively mitigated the inflammatory response via decreasing the number of microglia (labelled with Iba1), result in the expression of IL-1α, IL-2, IL-6, IL-18 and TNF-α downregulating, but the level of IL-10 and BDNF increases in the injured spinal cord. Moreover, FOs enhanced neuronal survival, ameliorated the scar cavities, and improved behaviors, including Basso mouse scale (BMS) scores and the gait of mice after SCI. Together, these results demonstrated that administration of FOs showed superior functional recovery effects in a SCI model. Also, FOs may modulate inflammatory activities by regulating the expression of proinflammatory factors, decreasing the production of inflammatory cells, and promoting functional recovery through the MAPK pathway following SCI.
- Published
- 2020
13. Possibly of angiotesin II-induced brain microvascular endothelial cell injury through oxidative stress
- Author
-
Bin Zhang, Huiqing Liu, Xiu-Mei Zhang, Ru Sun, Xinbing Wei, Xia Sun, and Zi-ying Wang
- Subjects
Pharmacology ,chemistry.chemical_classification ,medicine.medical_specialty ,Reactive oxygen species ,Angiotensin II receptor type 1 ,biology ,medicine.disease_cause ,Malondialdehyde ,Angiotensin II ,Superoxide dismutase ,Endothelial stem cell ,chemistry.chemical_compound ,Endocrinology ,Losartan ,chemistry ,Internal medicine ,cardiovascular system ,biology.protein ,medicine ,hormones, hormone substitutes, and hormone antagonists ,Oxidative stress ,Food Science ,medicine.drug - Abstract
An increasing number of studies suggest that angiotensin (Ang) Ⅱ contributes to the pathology of cerebrovascular disease possibly through injuring of the brain microvascular endothelial cells (BMEC), but the mechanisms involved are not well elucidated. Recent studies reveal the importance of Ang Ⅱ in reactive oxygen species induction and endothelial injury. Hence, the present study investigated the involvement of oxidative stress in Ang Ⅱ-induced BMEC injury. Our results showed that 10^(-6) mol/L Ang Ⅱ increased lactate dehydrogenase (LDH) leakage and inhibited the viability of primary cultured BMEC. Incubation with 10^(-6) mol/L of Ang Ⅱ for 48 hr increased the extracellular and intracellular malondialdehyde (IVIDA) content and decreased the activities of intracellular glutathione peroxidase (GSH-Px) and superoxide dismutase (SOD) significantly. These effects were abolished by pretreatment with the selective AT1 receptor antagonist losartan, but not with the AT2 selective antagonist PD 123319. Combining Losartan with PD 123319 neither diminished nor promoted the effect of losartan alone. These findings indicated that Ang Ⅱ induced injury of BMEC may result from oxidative stress by activating AT1 receptors. This injury may in turn lead to the development of cerebrovascular disease.
- Published
- 2020
14. Cynandione A alleviates neuropathic pain through spinal microglial interleukin-10/β-endorphin expression following α7 nicotinic acetylcholine receptor activation
- Author
-
Hao Liu, Qiao-Qiao Han, Jun-Ping Ao, Min Yin, Yong-Xiang Wang, and Zi-Ying Wang
- Subjects
Interleukin 10 ,α7 nicotinic acetylcholine receptor ,business.industry ,Cynandione A ,Neuropathic pain ,Medicine ,Pharmacology ,business - Abstract
Background Cynandione A, an acetophenone isolated from Cynanchum Wilfordii Radix, exhibits antihypersensitivity effects in neuropathic pain. This study sought to explore the target molecule and mechanisms underlying cynandione A mechanical antiallodynia, particularly related to the spinal glial expression of IL-10/β-endorphin, cAMP/PKA/p38/CREB signaling and α7 nicotinic acetylcholine receptor (α7 nAChR) activation. Methods IL-10 and β-endorphin in the spinal cord of spinal nerve ligation-induced neuropathic pain rats and cultured primary microglia were assessed by qRT-PCR and ELISA assays. Double immunofluorescence staining of IL-10, β-endorphin with glial and neuronal cellular biomarkers was also conducted in the spinal cord and cultured primary microglia. Microglial phosphorylation of PKA, p38, CREB and STAT3 were detected using western blot. Results Cynandione A significantly attenuated mechanical allodynia in neuropathic rats and substantially increased IL-10 and β-endorphin (but not dynorphin A) expression in the spinal cords and cultured primary microglia. The IL-10 antibody attenuated cynandione A-induced spinal or microglial gene expression of β-endorphin and mechanical antiallodynia, whereas the β-endorphin antiserum blocked cynandione A-induced mechanical antiallodynia but not spinal or microglial IL-10 gene expression. The α7 nAChR antagonist methyllycaconitine significantly declined cynandione A-induced mechanical antiallodynia and spinal or microglial expression of IL-10 and β-endorphin. Cynandione A stimulated microglial phosphorylation of PKA, p38 and CREB, which was inhibited by methyllycaconitine. Treatment with the adenylyl cyclase inhibitor DDA, PKA inhibitor H-89, p38 inhibitor SB203580 and CREB inhibitor KG501 attenuated cynandione A-induced mechanical antiallodynia and spinal or microglial expression of IL-10 and β-endorphin. Cynandione A stimulated spinal phosphorylation of the transcription factor STAT3, which was inhibited by methyllycaconitine, H-89 and the IL-10 antibody. The STAT3 inhibitor NSC74859 weakened cynandione A-induced mechanical antiallodynia and spinal expression of β-endorphin. Conclusion Our results illustrate that cynandione A produces mechanical antiallodynia through spinal microglial expression of IL-10 via the cAMP/PKA/p38/CREB signaling and subsequent β-endorphin expression via the IL-10/STAT3 signaling, following α7 nAChR activation.
- Published
- 2020
15. The spinal microglial IL-10/β-endorphin pathway accounts for cinobufagin-induced mechanical antiallodynia in bone cancer pain following activation of α7-nicotinic acetylcholine receptors
- Author
-
Usman Ali, Hai-Yun Wu, Zi-Ying Wang, Evhy Apryani, Xiao-Fang Mao, Xin-Yan Li, Khalil Ali Ahmad, and Yong-Xiang Wang
- Subjects
Male ,alpha7 Nicotinic Acetylcholine Receptor ,medicine.drug_class ,Immunology ,Bone Neoplasms ,Pharmacology ,lcsh:RC346-429 ,Cellular and Molecular Neuroscience ,chemistry.chemical_compound ,Animals ,Medicine ,IL-10/β-endorphin pathway ,Rats, Wistar ,Cinobufagin ,lcsh:Neurology. Diseases of the nervous system ,Methyllycaconitine ,business.industry ,Research ,General Neuroscience ,beta-Endorphin ,Chronic pain ,Dynorphin A ,Cancer Pain ,medicine.disease ,Spinal cord ,Receptor antagonist ,Interleukin-10 ,Rats ,Bufanolides ,Nicotinic acetylcholine receptor ,Nociception ,medicine.anatomical_structure ,Spinal Cord ,Neurology ,chemistry ,Hyperalgesia ,Female ,Microglia ,α7-nicotinic acetylcholine receptor (α7-nAChR) ,business - Abstract
Background Cinobufagin is the major bufadienolide of Bufonis venenum (Chansu), which has been traditionally used for the treatment of chronic pain especially cancer pain. The current study aimed to evaluate its antinociceptive effects in bone cancer pain and explore the underlying mechanisms. Methods Rat bone cancer model was used in this study. The withdrawal threshold evoked by stimulation of the hindpaw was determined using a 2290 CE electrical von Frey hair. The β-endorphin and IL-10 levels were measured in the spinal cord and cultured primary microglia, astrocytes, and neurons. Results Cinobufagin, given intrathecally, dose-dependently attenuated mechanical allodynia in bone cancer pain rats, with the projected Emax of 90% MPE and ED50 of 6.4 μg. Intrathecal cinobufagin also stimulated the gene and protein expression of IL-10 and β-endorphin (but not dynorphin A) in the spinal cords of bone cancer pain rats. In addition, treatment with cinobufagin in cultured primary spinal microglia but not astrocytes or neurons stimulated the mRNA and protein expression of IL-10 and β-endorphin, which was prevented by the pretreatment with the IL-10 antibody but not β-endorphin antiserum. Furthermore, spinal cinobufagin-induced mechanical antiallodynia was inhibited by the pretreatment with intrathecal injection of the microglial inhibitor minocycline, IL-10 antibody, β-endorphin antiserum and specific μ-opioid receptor antagonist CTAP. Lastly, cinobufagin- and the specific α-7 nicotinic acetylcholine receptor (α7-nAChR) agonist PHA-543613-induced microglial gene expression of IL-10/β-endorphin and mechanical antiallodynia in bone cancer pain were blocked by the pretreatment with the specific α7-nAChR antagonist methyllycaconitine. Conclusions Our results illustrate that cinobufagin produces mechanical antiallodynia in bone cancer pain through spinal microglial expression of IL-10 and subsequent β-endorphin following activation of α7-nAChRs. Our results also highlight the broad significance of the recently uncovered spinal microglial IL-10/β-endorphin pathway in antinociception.
- Published
- 2020
16. Thalidomide alleviates neuropathic pain through microglial IL-10/β-endorphin signaling pathway
- Author
-
Meng-Yan Deng, Qiao-Qiao Han, Rana Muhammad Shoaib, Xin-Yan Li, Khalil Ali Ahmad, Yong-Xiang Wang, and Zi-Ying Wang
- Subjects
Male ,(+)-Naloxone ,Pharmacology ,Biochemistry ,Proinflammatory cytokine ,medicine ,Animals ,Rats, Wistar ,Cells, Cultured ,Multiple myeloma ,Lenalidomide ,Dose-Response Relationship, Drug ,Microglia ,business.industry ,beta-Endorphin ,medicine.disease ,Pomalidomide ,Interleukin-10 ,Rats ,Thalidomide ,medicine.anatomical_structure ,Neuropathic pain ,Neuralgia ,business ,Immunosuppressive Agents ,Signal Transduction ,medicine.drug - Abstract
Thalidomide is an antiinflammatory, antiangiogenic and immunomodulatory agent which has been used for the treatment of erythema nodosum leprosum and multiple myeloma. It has also been employed in treating complex regional pain syndromes. The current study aimed to reveal the molecular mechanisms underlying thalidomide-induced pain antihypersensitive effects in neuropathic pain. Thalidomide gavage, but not its more potent analogs lenalidomide and pomalidomide, inhibited mechanical allodynia and thermal hyperalgesia in neuropathic pain rats induced by tight ligation of spinal nerves, with ED50 values of 44.9 and 23.5 mg/kg, and Emax values of 74% and 84% MPE respectively. Intrathecal injection of thalidomide also inhibited mechanical allodynia and thermal hyperalgesia in neuropathic pain. Treatment with thalidomide, lenalidomide and pomalidomide reduced peripheral nerve injury-induced proinflammatory cytokines (TNFα, IL-1β and IL-6) in the ipsilateral spinal cords of neuropathic rats and LPS-treated primary microglial cells. In contrast, treatment with thalidomide, but not lenalidomide or pomalidomide, stimulated spinal expressions of IL-10 and β-endorphin in neuropathic rats. Particularly, thalidomide specifically stimulated IL-10 and β-endorphin expressions in microglia but not astrocytes or neurons. Furthermore, pretreatment with the IL-10 antibody blocked upregulation of β-endorphin in neuropathic rats and cultured microglial cells, whereas it did not restore thalidomide-induced downregulation of proinflammatory cytokine expression. Importantly, pretreatment with intrathecal injection of the microglial metabolic inhibitor minocycline, IL-10 antibody, β-endorphin antiserum, and preferred or selective μ-opioid receptor antagonist naloxone or CTAP entirely blocked thalidomide gavage-induced mechanical antiallodynia. Our results demonstrate that thalidomide, but not lenalidomide or pomalidomide, alleviates neuropathic pain, which is mediated by upregulation of spinal microglial IL-10/β-endorphin expression, rather than downregulation of TNFα expression.
- Published
- 2021
17. The Effect of Terpenoids ofDipsacus AsperoidesAgainst Alzheimer's Disease and Development of Simultaneous Analysis by High Performance Liquid Chromatography
- Author
-
Wan Kyunn Whang, Zi Ying Wang, and Xiaodan Zhang
- Subjects
Pharmacology ,Hplc analysis ,Chromatography ,Chemistry ,Active components ,Plant Science ,General Medicine ,High-performance liquid chromatography ,Terpenoid ,Complementary and alternative medicine ,Drug Discovery ,Effective treatment ,Radix ,Dipsacus asperoides - Abstract
Dipsaci Radix has been proved to represent an effective treatment strategy for Alzheimer's disease (AD), but the potential active components in Dipsaci Radix have not been evaluated by an AD-related bioassay. In this study, water fraction of Dipsaci Radix had been shown to have highest inhibitory effect on the AD-related activity tests, including inhibition of acetylcholinesterase (AChE), butyrylcholinesterase (BChE), β-site amyloid precursor protein cleaving enzyme 1 (BACE1), and advanced glycation end-product (AGE) formation. Therefore, a bioassay-guided approach yielded eleven terpenoid compounds (DR1-11) isolated from water fraction of Dipsaci Radix. Compounds (DR2,3,7 and 11) were stronger inhibitors of AChE. The BChE inhibitory effect of saponins was more positive than that of iridoids (DR1,4). Compounds (DR6,7,9-11) were good inhibitors of BACE1. Compounds (DR7-11) were more effective than positive control on the inhibition of AGE formation. Moreover, we firstly suggested concomitant new connections between the structure of Dipsaci Radix's isolated terpenoid compounds with AChE inhibitory activities and AGE formation. The study also represented that Dipsaci Radix was therapeutic for treating AD and dipsacus saponin XI (DR11) might be one of its active components. Our findings significantly provided the new foundation of the potential capacity bioactive components from Dipsaci Radix for AD remedy.
- Published
- 2021
18. Neuroprotective Natural Products for the Treatment of Parkinson's Disease by Targeting the Autophagy-Lysosome Pathway: A Systematic Review
- Author
-
Chuanbin Yang, Yingyu Huang, Sandeep Malampati, Mei-Xiang Li, Ju-Xian Song, Zi-Ying Wang, Jing-Yi Liu, and Min Li
- Subjects
0301 basic medicine ,Pharmacology ,Pathology ,medicine.medical_specialty ,Parkinson's disease ,business.industry ,Dopaminergic ,Autophagy ,Protein aggregation ,medicine.disease ,Neuroprotection ,Pathogenesis ,03 medical and health sciences ,030104 developmental biology ,medicine.anatomical_structure ,In vivo ,Lysosome ,medicine ,business - Abstract
The autophagy-lysosome pathway (ALP) is a primary means by which damaged organelles and long-lived proteins are removed from cells and their components recycled. Impairment of the ALP has been found to be linked to the pathogenesis of Parkinson's disease (PD), a chronic neurodegenerative disorder characterized by the accumulation of protein aggregates and loss of dopaminergic neurons in the midbrain. In recent years, some active compounds derived from plants have been found to regulate the ALP and to exert neuroprotective effects in experimental models of PD, raising the possibility that autophagy enhancement may be an effective therapeutic strategy in PD treatment. In this review, we summarize recent findings of natural products that enhance ALP and thereby protect against PD. Research articles were retrieved from PubMed using relevant keywords in combination. Papers related to the topic were identified, and then the reliability of the experiments was assessed in terms of methodology. The results suggest that targeting the ALP with natural products is a promising strategy for PD treatment. However, risk of bias exists in some studies due to the defective methodology. Rigorous experimental design following the guidelines of autophagy assays, molecular target identification and in vivo efficacy evaluation is critical for the development of ALP enhancers for PD treatment in future studies. Copyright © 2017 John Wiley & Sons, Ltd.
- Published
- 2017
19. Involvement of d-amino acid oxidase in cerebral ischaemia induced by transient occlusion of the middle cerebral artery in mice
- Author
-
Hai-Yun Wu, Zi-Ying Wang, Meng-Jing Zhao, Hao Liu, Qiao-Qiao Han, Xiao-Fang Mao, and Yong-Xiang Wang
- Subjects
0301 basic medicine ,D-Amino-Acid Oxidase ,Male ,Pharmacology ,Neuroprotection ,Brain Ischemia ,03 medical and health sciences ,Mice ,0302 clinical medicine ,medicine.artery ,medicine ,Animals ,cardiovascular diseases ,Pentobarbital ,ED50 ,Injections, Intraventricular ,Oxidase test ,Glial fibrillary acidic protein ,biology ,Chemistry ,Oxidative deamination ,Infarction, Middle Cerebral Artery ,Research Papers ,Disease Models, Animal ,030104 developmental biology ,Middle cerebral artery ,biology.protein ,030217 neurology & neurosurgery ,Immunostaining ,Intracellular - Abstract
Background and purpose d-Amino acid oxidase (DAAO) is a flavine adenine dinucleotide-containing flavoenzyme and specifically catalyses oxidative deamination of d-amino acids. This study aimed to explore the association between increased cerebral DAAO expression or enzymic activity and the development of cerebral ischaemia. Experimental approach A mouse model of transient (90 min) middle cerebral artery occlusion (MCAO) was established, and western blotting, enzymic activity assay, and fluorescent immunostaining techniques were used. Key results The expression and enzymic activity of DAAO increased over time in the cortical peri-infarct area of the mice subjected to transient MCAO. The DAAO was specifically expressed in astrocytes, and its double immunostaining with the astrocytic intracellular marker, glial fibrillary acidic protein, in the cortical peri-infarct area was up-regulated following ischaemic insult, with peak increase on Day 5 after MCAO. Single intravenous injection of the specific and potent DAAO inhibitor Compound SUN reduced the cerebral DAAO enzymic activity and attenuated neuronal infarction and neurobehavioural deficits with optimal improvement apparent immediately after the MCAO procedure. The neuroprotective effect was dose dependent, with ED50 values of 3.9-4.5 mg·kg-1 . Intracerebroventricular injection of the DAAO gene silencer siRNA/DAAO significantly reduced cerebral DAAO expression and attenuated MCAO-induced neuronal infarction and behavioural deficits. Conclusions and implications Our results, for the first time, demonstrated that increased cerebral astrocytic DAAO expression and enzymic activity were causally associated with the development of neuronal destruction following ischaemic insults, suggesting that targeting cerebral DAAO could be a potential approach for treatment of neurological conditions following cerebral ischaemia.
- Published
- 2018
20. Immunomodulation of Chinese Herbal Medicines on NK cell populations for cancer therapy: A systematic review
- Author
-
Daniel Man-Yuen Sze, Hao Liu, Yu-Cong Zhou, Wei Song, Usman Ali, and Zi-Ying Wang
- Subjects
Oncology ,medicine.medical_specialty ,Angelica sinensis ,medicine.medical_treatment ,Metastasis ,Immunomodulation ,03 medical and health sciences ,Ginseng ,0302 clinical medicine ,Neoplasms ,Internal medicine ,Drug Discovery ,medicine ,Adjuvant therapy ,Animals ,Humans ,Medicine, Chinese Traditional ,030304 developmental biology ,Pharmacology ,0303 health sciences ,Chemotherapy ,biology ,business.industry ,Cancer ,medicine.disease ,biology.organism_classification ,Antineoplastic Agents, Phytogenic ,Killer Cells, Natural ,Radiation therapy ,Clinical trial ,030220 oncology & carcinogenesis ,business ,Drugs, Chinese Herbal - Abstract
Ethnopharmacological relevance Immunomodulation has become a crucial modality for cancer treatment. Chinese Herbal Medicines (CHMs) are expected as adjuvant therapy for immunomodulation against cancer, but face the key challenge of poor scientific evidence. Changes of natural killer (NK) cells on numbers and/or cytotoxicity are a novel respect to evaluate the immunomodulation of CHMs. Aim of the study The purpose of this review is to investigate the immunomodulation of Chinese Herbal Medicines (CHMs) on NK cell populations for cancer therapy. Materials and methods A systematic review was conducted and outside mainstream electronic databases were screened for potential reference articles. This review tried to report and critically analyzed all the correlative studies, especially these clinical trials (3 CHM extracts and 11 CHM formulas). Results Evidence-based functions of CHMs against cancer could be summarized as: (1) enhancement of NK cells activity or relative percentage; (2) prevention of tumor growth and metastasis; (3) relief on side-effects or complications of therapeutic strategies (i.e. chemotherapy, radiotherapy and resection). Briefly, most of cellular studies and two thirds animal studies were based on the extract or components of single herbs, whilst most of clinical trials were keen on formula or prescription of CHMs. The main components of CHMs were demonstrated active on promoting the cytotoxicity of NK cells, including Angelica sinensis, Ganoderma lucidum, Panax ginseng, Radix Astragali, Lentinus edodes, etc. Conclusions This comprehensive review demonstrated NK cells activity was positively associated with quality of life but not survival benefit of cancer patients. Thus exploring the roles of NK cells in adjuvant therapy against cancer is confirmed to be beneficial to explore the underlying relationship between immunomodulation and quality of life.
- Published
- 2021
21. Strategies for brain-targeting liposomal delivery of small hydrophobic molecules in the treatment of neurodegenerative diseases
- Author
-
Sravan Gopalkrishnashetty Sreenivasmurthy, Min Li, Ju-Xian Song, Jing-Yi Liu, and Zi-Ying Wang
- Subjects
0301 basic medicine ,Pharmacology ,Liposome ,business.industry ,Brain ,Neurodegenerative Diseases ,Bioinformatics ,Small molecule ,Neuroprotection ,Brain targeting ,03 medical and health sciences ,030104 developmental biology ,0302 clinical medicine ,Neuroprotective Agents ,030220 oncology & carcinogenesis ,Drug Discovery ,Liposomes ,Medicine ,Animals ,Humans ,Older people ,business ,Hydrophobic and Hydrophilic Interactions - Abstract
Neurodegenerative diseases (NDs), including Alzheimer’s disease (AD) and Parkinson’s disease (PD), threaten the health of an ever-growing number of older people worldwide; so far, there are no effective cures. Significant efforts have been devoted to developing new drugs for NDs in recent years, and some small molecules have been shown to be promising in preclinical studies. However, the major challenge for brain-targeting drugs is how to efficiently deliver the drugs across the blood–brain barrier (BBB) to desired targets. To address this issue, liposomal delivery systems have proved to be ideal carriers for neuroprotective small molecules. Here, we summarize recent advances in the brain-targeting liposomal delivery of small hydrophobic molecules (SHMs) and propose strategies for developing liposomal SHMs as disease-modifying neurotherapeutics for NDs.
- Published
- 2018
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.